Reasons for exclusion from thrombolytic therapy following acute ischemic stroke.
Despite evidence for the efficacy of thrombolytic therapy in acute ischemic stroke, only 1 to 7% of patients receive this therapy. The authors sought to determine the reasons for exclusion from tissue plasminogen activator (tPA) in an acute setting and found avoidable causes in 18% of patients. Improvements in intrahospital coordination would increase the number of patients who might benefit from tPA treatment at the authors' center.
Cocho
D
D
Cerebrovascular Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Spain. dcocho@hsp.santpau.es
Belvís
R
R
Martí-Fàbregas
J
J
Molina-Porcel
L
L
Díaz-Manera
J
J
Aleu
A
A
Pagonabarraga
J
J
García-Bargo
D
D
Mauri
A
A
Martí-Vilalta
J-L
JL
D000208:Acute Disease; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D002543:Cerebral Hemorrhage / Q000188:drug therapy / Q000453:epidemiology; D002544:Cerebral Infarction / Q000188:drug therapy / Q000453:epidemiology; D000075202:Contraindications; D042241:Early Diagnosis; D004636:Emergency Service, Hospital / Q000706:statistics & numerical data*; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D002546:Ischemic Attack, Transient / Q000188:drug therapy / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009462:Neurology; D011994:Recombinant Proteins / Q000627:therapeutic use; D012017:Referral and Consultation / Q000706:statistics & numerical data; D020458:Third-Party Consent; D015912:Thrombolytic Therapy / Q000706:statistics & numerical data*; D013997:Time Factors; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use*; D016312:Treatment Refusal
D005343:Fibrinolytic Agents; D011994:Recombinant Proteins; D010959:Tissue Plasminogen Activator